$ANIP News

Canaccord Genuity Initiates Coverage On ANI Pharmaceuticals with Hold Rating, Announces Price Target of $91

ANI Pharmaceuticals Reveals Trial Court Denied Company’s Motion For A New Trial And Judgment As A Matter Of Law For Unjust Enrichment; Co. Intends To Appeal Rulings To The Delaware Supreme Court And Continue To Seek To Recover The Value Of The Assets It Sold To CG Oncology In 2010

ANI Pharmaceuticals Announces Topline Data From Its Phase 4 SYNCHRONICITY Clinical Trial Of The Fluocinolone Acetonide Intravitreal Implant; Trial Met Both Co-Primary Endpoints

Guggenheim Reiterates Buy on ANI Pharmaceuticals, Maintains $124 Price Target

ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple

ANI Pharmaceuticals, Inc. (ANIP) Q1 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation

ANI Pharmaceuticals (NASDAQ:ANIP) Crushes Q1 Estimates, Raises Full-Year Guidance

ANI Pharmaceuticals Raises FY2026 Adj EPS Guidance from $8.83-$9.34 to $9.19-$9.69 vs $9.07 Est; Raises FY2026 Sales Guidance from $1.055B-$1.115B to $1.080B-$1.140B vs $1.050B Est.

ANI Pharmaceuticals Q1 Adj. EPS $2.05 Beats $1.30 Estimate, Sales $237.462M Beat $207.565M Estimate.

ANI Pharmaceuticals Announces Launch Of Pimozide Tablets 1 Mg And 2 Mg, Generic Version Of Reference Listed Drug Orap, With 180-Day CGT Exclusivity

ANI Pharmaceuticals Launches Carbamazepine Extended-Release Capsules, Generic Version Of Carbatrol

ANI Pharmaceuticals Looks Undervalued As Cortrophin Drives Rare Disease Growth

ANI Pharma Launches Isosorbide Mononitrate Tablet USP, Generic Version Of Reference Listed Drug Monoket

ANI Pharma Announces Publication Of Results From NEW DAY Clinical Trial Involving ILUVIEN For Use In Patients With Diabetic Macular Edema In Ophthalmology, The Journal Of The American Academy Of Ophthalmology

Janux Therapeutics Secures $35M Milestone Payment From BMY Deal

OCGN Completes Early Enrollment in Pivotal Stargardt Disease Study

Assessing ANI Pharmaceuticals (ANIP) Valuation After Recent Share Price Choppiness

Kodiak Q4 Loss Wider Than Expected, Pipeline Development in Focus

AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD